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Background: Numerous tools and items have been developed in all health areas to assess the risk of bias of
randomized controlled trials (RCTs). The Cochrane Collaboration (CC) released a new tool to assess bias in RCTs,
based on empirical evidence quantifying the association between some design features and estimates of treatment
effects (TEs). However, this evidence is limited to medicine and investigating a selected set of components. No such
studies have been conducted in other health areas such as Physical Therapy (PT) and allied health professions.
Evidence specific to the PT area is needed to understand and quantify the association between design features and
TE estimates to inform practice and decision-making in this field. The overall goal of this project is to provide
direction for the design, conduct, reporting and bias assessment of PT RCTs. We will achieve this through the
following specific objectives and methods.
Methods/Design: 1) to measure the association between methodological components and other factors
(for example, PT area, type of intervention, type of outcomes) and TE estimates in RCTs in PT, 40 randomly selected
meta-analyses of RCTs involving PT interventions will be identified from the Cochrane Database of Systematic
Reviews. Trials will be evaluated independently by two reviewers using the most commonly used tools in the PT
field. A two-level analysis will be conducted using a meta-meta-analytic approach; 2) to identify relevant items to
evaluate risk of bias of PT trials, an exploratory factor analysis (EFA) will be used to identify the latent structure of
the items; 3) to develop guidelines for the design, conduct, reporting, and risk of bias assessment of PT RCTs, items
obtained from the factor analysis and the meta-epidemiological approach will be further evaluated by experts in
PT through a web-based survey following a Delphi procedure.
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Discussion: The results of this project will have a direct impact on research and practice in PT and are valuable to
a number of stakeholders: researchers when designing, conducting, and reporting trials; systematic reviewers and
meta-analysts when synthesizing trial results; physiotherapists when making day-to-day treatment decision; and,
other healthcare decision-makers, such as those developing policy or practice guidelines.
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procedureBackground
Randomized controlled trials (RCTs), as well as system-
atic reviews (SRs) and meta-analyses (MAs) of these
trials, are considered the gold standard to evaluate the
efficacy and effectiveness of health care interventions
[1]. The results from these studies are crucial for
informing patients, clinicians and decision/policy-makers
about the best treatments to be implemented to improve
patient outcomes and the efficiency of the health care
system. Assessing the methodological quality of trials is
an essential component of systematic reviews, since only
the highest quality evidence should be used to inform
clinical and policy decisions. An accurate quality assess-
ment is imperative in the synthesis of study findings in
order to appropriately interpret results and effectively
guide health care [2]. Quality assessment of studies has
been used to: determine a minimum quality threshold
for the selection of primary studies for systematic
reviews, assist in determining the strength of inferences,
and more importantly, to guide recommendations for
future research, policy decisions, and clinical practice [2].
It has been demonstrated that different design features
of a trial can have a substantial impact on estimates of
treatment effects [3-7]. For example, it has been shown
that inadequate allocation concealment or lack of
double-blinding can overestimate treatment effects on
average by 18% and 9%, respectively [4,6,7]. Other fac-
tors such as method of randomization [8,9], follow-up
proportions, [10,11] and industry sponsorship [12,13]
have also been shown to influence the results of trials.
All of these factors lead to over-estimates of treatment
effects, or bias, at the trial level, and can lead to biased
or inaccurate results and conclusions in systematic
reviews and meta-analyses [3,4,9,10,14]. This ultimately
can have repercussions on decision-making and the
quality of patient care since biased interventions (for
example, interventions that are not as effective, inef-
fective, or perhaps even harmful) may lead to inappro-
priate expectations of impact, wasted resources and/or
inappropriate uptake of evidence, respectively.
While the impact of primary trial bias on evidence
synthesis has been recognized for years, the approach
to quality assessment has been inconsistent and contro-
versial [15]. Many tools (for example, Jadad, Chalmers,CONSORT, Delphi List, to name but a few) have been
used to determine quality of RCTs in different health
areas [15,16]. There is no agreement regarding which
tools are optimal to accurately determine trial quality.
Most tools have not been developed using scientifically
rigorous methods, lack reliability and/or have not been
fully validated [15]. In addition, the use of different tools
for evaluating the quality of primary research can lead to
different end results [17-19]. Thus, a clinical trial may be
rated on a quality scale disparate by different measure-
ment tools. This discrepancy in the evaluation of the
quality of research may skew interpretation, reporting,
and as a result, could potentially impact recommenda-
tions for clinical care. Finally, the tools include different
items, some of which relate more to the detail of
reporting rather than methodological quality.
As a result of these shortcomings with existing tools
and methods for quality assessment, there has been a
shift in the traditional scoring approach to the assess-
ment of trial quality. Instead of examining trial quality
with tools that have not been validated and often use
composite scores, the assessment of ‘risk of bias’ was
proposed in 2008 by the Cochrane Collaboration, one of
the most important and influential groups working on
evidence based practice worldwide [20]. The Risk of Bias
(RoB) tool was developed based on a growing body of
empirical evidence quantifying the association between
certain design features and estimates of treatment effects
(TEs). The RoB tool includes six domains: sequence
generation; allocation concealment; blinding; missing
outcome data; selective outcome reporting; and ‘other
sources of bias’ (for example, early stopping for benefit,
design-specific features such as adequate wash-out
period in cross-over trials). Other methodological com-
ponents within the RoB tool as well as other compo-
nents that have traditionally been used to determine trial
quality in health research have not been investigated;
hence the evidence base is limited and incomplete. Fur-
thermore, recent research [5,19] recommends further
testing of the RoB tool to gain a better understanding of
its psychometric properties, as well as to validate the
tool in a wider range of research fields. Additional infor-
mation will help users in applying and interpreting the
results of the RoB tool.
Armijo-Olivo et al. Systematic Reviews 2013, 2:88 Page 3 of 8
http://www.systematicreviewsjournal.com/content/2/1/88Most of the empirical evidence regarding the relation-
ship between trial components and treatment effect
estimates comes from RCTs in the area of medicine and
is based only on dichotomous outcomes [4,6,7]. No such
studies have been conducted in other health areas such
as the allied health professions, including physical ther-
apy (PT). RCTs conducted in PT have unique features
compared to drug trials conducted in medicine. PT
interventions are classified as complex interventions [21]
comprised of diverse facets that may affect the trial
results, such as the type of therapy and its intensity, a
standardized or individually tailored approach, and the
skills and experience of the therapists. In addition,
because of the nature of PT interventions (for example,
manual therapy, exercises), blinding of the therapists
and or the patients is not always possible. Appropriate
blinding of participants and all key study personnel,
therefore, is unlikely to be accomplished for most PT
trials; however, blinding of outcome assessment has
been used as a proxy quality measure without validation.
Therefore, it is necessary that empirical evidence is
performed and expanded in the area of PT and allied
health professions in order to determine the factors that
affect treatment effects estimates in these trials to
provide accurate results to the clinical community. In
addition, this information is urgently needed to develop
guidelines for designing, conducting, and implementing
PT trials as well as providing clear benchmarks to assess
the risk of bias of PT trials in systematic reviews and
meta-analyses and ultimately the strength of evidence
for decision-making.
Therefore, the overall goals of this project are to
provide direction for the design, conduct, and reporting
of allied health RCTs, especially Physical Therapy (PT)
and provide clear benchmarks for evaluating the RoB of
RCTs in this area.
We will achieve this through the following specific
objectives:
1) To measure the association between
methodological components and treatment
effects (TE) estimates in RCTs in PT;
2) To determine the influence of other factors
(for example, clinical area, type of treatment,
type of outcomes) on TE estimates;
3) To identify the underlying component
structure of items to evaluate risk of bias
of PT trials;
4) To identify relevant items to evaluate risk of bias of
PT trials through experts’ opinion;
5) To develop guidelines for the design, conduct,
reporting, and implementation of PT RCTs and
provide clear benchmarks for evaluating the RoB of
PT RCTs.Methods/Design
This Research protocol has been approved by the Ethics
Board of the University of Alberta (Pro00038172).
Objectives 1, 2 and 3
Study search
Meta-analyses and their RCTs will be obtained by
searching the Cochrane Database of Systematic Reviews
(meta-analyses) using the words physical therapy or
physiotherapy, rehabilitation, exercise, electrophysical
agents, acupuncture, massage, Transcutaneous Electrical
Nerve Stimulation (TENS), interferential current, ultra-
sound, stretching, chest therapy, pulmonary rehabilita-
tion, manipulative therapy, mobilization. Meta-analyses
and their trials will be included if: 1) they included at
least five RCTs comparing at least two interventions, at
least one of which is currently or potentially part of PT
practice according to the World Confederation for PT
(WCPT) [22]; 2) the interventions in the trial will be
applied to human subjects who were representative of
subjects to whom the intervention might be applied in
clinical PT practice; 3) the allocation of subjects to
interventions was random or reported to be random; and
4) the authors provided quantitative data of treatment
estimates.
Study selection
Two reviewers (physical therapists, both with at least 18
years of experience in physical therapy field and
research) will independently screen the abstracts of the
meta-analyses found in the Cochrane database and will
analyze all papers initially selected by the abstract or title
using the pre-defined inclusion/exclusion criteria (des-
cribed above). Each criterion will be graded on a yes/no
basis. Discrepancies between reviewers regarding inclu-
sion will be resolved through consensus or in consultation
with a third reviewer.
Sample size
Most meta-epidemiological work carried out until now
has not formally performed sample size calculations
since they have been exploratory in nature. However,
according to a recent report, [23] most of these studies
are under powered due to the small magnitude of the
differences between trials with and without the quality
domain, small sample sizes, and the high heterogeneity
of the datasets. Based on this, the authors recommended
assembling a homogenous set of meta-analyses and trials
in a specific area of research and to have a larger num-
ber of trials included to increase the power of the study.
Since this study is prospective, the magnitude of the dif-
ference between trials conducted with certain domains
of trial quality and those that do not, is not known.
However, it could be anticipated that a difference in
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without quality domains, as reported in previous meta-
epidemiological work, would be obtained [11,24]. This
magnitude of difference has been argued to correspond
to one quarter to one half of a typical treatment effect
found for interventions in areas similar to physical
therapy. Thus, this difference would be relevant to the
field. Therefore, sample size calculation for this project
will be based on the following: information in a recent
report, [23] research team, human resources, project
budget, similar studies involving a continuous outcome,
[11,24,25] and based on a search regarding possible
meta-analyses from the Cochrane Collaboration to be
included with outcomes of interest. We will target a
number of 400 trials included in 40 meta-analyses
approximately. This number of trials is almost double
the number of trials included in previous meta-
epidemiological work using continuous outcomes and/or
evaluating interventions, and outcomes that could be
comparable to the area of the PT.
A unique code generated by the Reference Manager
bibliographic program will be assigned to each meta-
analysis and trial that meets the inclusion criteria. This
code will be used to randomly select the studies to be
analyzed for this project and also to randomize the order
of evaluation. The first author will randomly select each
of the meta-analyses (MA) to be included, and accom-
panying trials, by drawing the code of the selected MA
from an opaque envelope.
Data extraction and quality assessment
All of the trials will be evaluated independently by two
reviewers using seven tools with their items (that is,
Delphi List, PEDro, Maastricht, Maastricht-Amsterdam
List, Bizzini, van Tulder and Jadad) that are most com-
monly used or most validated in the PT field [15].
Altogether 45 different items obtained from the seven
tools will be used to evaluate the trials included for
analysis in this study. All reviewers will receive the same
training and guidance and will be provided with stan-
dardized guidelines to assess and to use all 45 items
in each study. The definition for meaning of items
was obtained from the guidelines of original tools and
will be compiled and distributed to all reviewers for
conducting the scoring. A three point scale (yes, no,
unclear), which was the most common response for-
mat in the original tools, will be used to assess the
items from these tools.
In addition, the Cochrane Collaboration Risk of Bias
(RoB) tool introduced in 2008 [20] will be used to eva-
luate the risk of bias of these trials. Additional information
regarding individual trials such as type of interventions
and their details such as intensity, frequency, and dosage
will be collected. Furthermore, information related to typeof outcomes (that is, objective, subjective) and their esti-
mates (that is, mean, SD, sample size), funding source,
publication year, design characteristics, statistical analysis,
and sample size will be extracted.
A data extraction template hosted in an access pro-
gram database will be used to store data extraction
results.
Reviewers
A review panel comprised of five reviewers with experi-
ence in different areas of health sciences research will
participate in this study.
Reviewer training will be carried out with ten papers
not included in the set of papers to be reviewed. Each of
the ten training papers will be independently reviewed
by all member of the review panel and then discussed by
the panel. The first author will perform the training for
all raters and will make sure that all reviewers have
clarity regarding data extraction.
The two reviewers that assessed the same study will
compare their assessments. Any discrepancies will be
resolved by discussion between the two reviewers. If a
consensus rating would not be achieved, then the two
reviewers will consult with a third reviewer (first author)
to achieve consensus. Consensus answers will be used
for all analyses.
Objectives 1 and 2: analysis
In order to determine the methodological trial compo-
nents that affect treatment effect estimates, a two-level
analysis will be conducted using a meta-meta-analytic
approach with a random-effects model to allow for
within and between meta-analyses heterogeneity [26].
The first level analysis (within meta-analysis) will be as
follows: the standardized effect size estimates will be
obtained for the primary outcome of each trial using the
guidelines established by Cohen [27]. The data from
each trial will be obtained from each meta-analysis. In
the case of studies appearing in more than one review,
the study will only be considered once in the meta-
analysis with the fewer number of overall studies. For
each meta-analysis and each trial component (for ex-
ample, allocation concealment, randomization, blinding),
included studies will be divided in two groups according
to the relevant quality item (that is, those adequately
addressing the item and those not). Two effect sizes will
be calculated for each meta-analysis. The first one corre-
sponding to the pooled effect size from those studies
having the characteristic of interest (for example, alloca-
tion concealment) and the other for those studies that
did not (for example, no or unclear allocation con-
cealment). Thus, for each meta-analysis, the difference
between pooled estimates from trials with (for example,
allocation concealment) and without the characteristic
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(among meta-analyses) will involve pooling the results of
the previous analysis (combined differences from all
meta-analyses) to describe the effect of the each trial
component across all meta-analyses. The effect sizes will
be combined at this stage using the DerSimonian and
Laird random effect models [28] to allow for between
meta-analysis heterogeneity. STATA statistical software
version 12 (College Station, TX: StataCorp LP 4905
Lakeway Drive College Station, Texas 77845–4512 USA)
will be used to perform these analyses.
Objective 3: analysis
Exploratory factor analysis (EFA) will be used to identify
the latent structure of the items from the seven PT
existing tools. First, the 45 items will be examined to be
sure that there was variability across the three response
options. Items with no variability will be deleted at this
point. The next step will be to estimate the number of
common factors. The Kaiser-Guttman rule (number of
components with eigenvalues greater than or equal to
one yielded by a principal components extraction, the
Scree test, and Kaiser’s image factoring followed by
varimax rotation will be used to identify the number of
common factors that underlay the structure of items
[29,30]. Following identification of the number of com-
mon items, the items will be subjected to an exploratory
factor analysis using principal axis extraction followed
by a varimax rotation and an oblique transformation. If
the correlations among factors in the oblique solution
are low, then the varimax rotation solution would be
retained, otherwise the oblique solution. Items that did
not load on any of the retained factors will be then
sequentially removed. Likewise, items with low factor
loadings will be removed (≤ 0.36). SPSS version 17 (SPSS
Inc., Chicago, IL, USA) will be used to perform all ana-
lyses [29,30]. After conducting the exploratory factor
analysis, the retained factors will be named by the first
author and then, discussed and verified by the members
of the review panel.
Objectives 4 and 5
Identification of items by experts
In order to identify relevant items to evaluate risk of bias
of PT trials through experts’ opinion; and to develop
guidelines for the design, conduct, reporting, and assess-
ment of RoB of PT RCTs, results of the factor analysis
will be considered along with the results of the meta-
epidemiological approach (that is, association between
methodological characteristics and TE) to make recom-
mendations regarding items to use when assessing risk
of bias of PT trials. Results of these analyses will be
compiled by the research team. If these two approaches
(factor analysis and meta-epidemiological approach)have contradictory results regarding items/factors to be
included when evaluating the risk of bias of PT trials,
items will be further evaluated by methodological and
research experts in PT field. They will provide input for
item reduction and selection providing face and content
validity evidence to these items.
The input of experts will be obtained through a web-
based survey following a Delphi procedure. The Delphi
technique has been recognized as an appropriate method
when the aim of the study is to reach group consensus
from individual expert opinion [31]. The Delphi procedure
is an interactive method, suitable for controversial
topics such as methodological quality/risk of bias of
primary research. It engages experts in the area of
interest who are asked to rate a set of items or ques-
tionnaire anonymously during consecutive rounds
while being provided with the aggregate responses of
prior rounds [32].
Items obtained from the analyses (factor analysis and
meta-epidemiological approach) and the evidence obtained
from the previous studies carried out by our team will be
presented to each of the PT experts. Each expert has to
choose the most relevant items s/he considers to evaluate
the quality/risk of bias for PT RCTs. Each expert will be
asked to formulate the following question for each item: ‘is
this item relevant to evaluate the quality/risk of bias for PT
RCTs?’ The answer options will use a nine-point Likert
scale (1 strongly disagree, 9 strongly agree), with a score of
5 indicating no opinion or not enough information or
experience to judge. Recommendations will be drafted by
the research team and will be presented to the expert’s
panel in two or three rounds of internet-based surveys
using a password-protected Delphi survey instrument.
In addition, personal data such as age, country, place of
work and details of research and clinical experience will
be collected. It should not take more than 15 minutes to
complete all of this activity each time.
Experts in PT field
Experts in PT research from different geographical areas
(for example, Canada, USA, Australia, France, Switzerland,
the Netherlands), will be indentified and contacted by
Email and they will be invited to participate. To be consi-
dered an expert in the field of PT, the participant has to
have the following:
1) Be a physical therapist or has worked in PT research
area for at least five years.
2) To have participated in at least one RCT or at
least three systematic reviews of interventions in
the area of PT.
3) To have knowledge/expertise regarding
methodological quality/risk of bias of primary
research, specifically RCTs in the area of PT.
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factors that are necessary to evaluate the risk of bias of PT
trials, a selected group of experts (with these characteris-
tics) are needed to be able to discern and determine which
of the items/factors are relevant to the study question.
Objectives 4 and 5: analysis
Recommendation-specific medians will be estimated for
each of the rounds. The inter-rater agreement between
participants in each round will be evaluated using the
intraclass correlation coefficient (ICC) with 95% confi-
dence intervals (CI).
Recommendations rated by < 10% of the experts will be
discarded. Recommendations rated by 10% to 90% of the
experts will be deferred until the second round. Recom-
mendations rated by > 90% of the experts will be discarded
if the overall median score fall within the bottom tertile (1
to 3) and deferred until the second round if the overall
median score is 4 to 6. Recommendations with overall
median scores within the top tertile (7 to 9) will be classi-
fied as follows: those rated by < 90% of the experts will be
deferred until the second round, and those rated by > 90%
of the experts will be classified as ‘high agreement’ if they
had an overall median score of 9 or as ‘agreement’ if they
had an overall median score of 7 or 8.
Data integration
Data from factor analysis, meta-epidemiological ap-
proach and Delphi procedure will be integrated by the
research team to develop guidelines for the design,
conduct, implementation, and reporting of PT RCTs. In
addition, guidelines to assess the RoB in PT RCTs will
be developed.
Discussion
Significance of the proposed research project
The results of this project will make an important
contribution to research and practice in the field of PT
and the allied health professions. This work will be valu-
able to a number of stakeholders including researchers,
systematic reviewers and meta-analysts, methodologists,
clinicians, and policy-makers. The results of the pro-
posed project will be the development and refinement of
methods of evidence synthesis for PT, so that the final
products are valid and meaningful to the end users.
First, this knowledge will provide guidance to resear-
chers for the design, conduct, implementation, and
reporting of RCTs in the PT field as well as other similar
health areas. Second, the findings of this project will
provide clearer benchmarks for evaluating the quality of
intervention trials for systematic reviewers and meta-
analysts in the area of PT. Third, the information will
allow practitioners to better determine the most ef-
fective interventions in order to provide their patientswith treatment options that are likely to yield greater
treatment benefits. Fourth, this information will help
policy-makers to make informed decisions regarding
implementation and support of PT interventions. The
results of this research have important implications
for knowledge translation by providing empirical evi-
dence that allows more accurate interpretation of
study findings. This is critical for informed decision-
making in order to understand the likely effect that
therapeutic interventions will have when applied in
practice. More informed decision making regarding
clinical care based on empirical evidence will ultima-
tely improve patient outcomes and will increase effi-
ciency in the health care system because interventions
that are most likely to improve patient outcomes will
be taken up and implemented.
Dissemination plan
We will develop guidelines for the design, conduct, im-
plementation, and reporting of PT trials and guidelines
to assess risk of bias in PT RCTs. These products will be
disseminated in different ways to a variety of target audi-
ences. Key groups with an interest in evidence based
practice in PT such as the Center of Evidence Based
Physiotherapy in the Netherlands, the Australian Center
for Evidence Based Physiotherapy, the World Confeder-
ation for PT Evidence Based Practice team, the Canadian
Physiotherapy Association, the Cochrane Bias Methods
Group, and the Cochrane Rehabilitation and Related
Therapies Field will be engaged. We will disseminate our
results to these groups through standard means (for
example, technical report, executive summary, peer-
reviewed publications) and will also work with these
groups to identify tools (for example, synopses, check-
lists) and methods (for example, list-servs, key meetings
and conferences) to distribute the results to a wider
audience. Results will also be disseminated to the editors
of PT journals. We will also develop innovative methods
of training and dissemination such as on-line modules
and web-based resources. An advisory working commit-
tee will be created to guide implementation of the
project findings. Researchers and clinicians in the field
will also be targeted using traditional dissemination
methods such as presentation at international confer-
ences (for example, International World PT conference),
seminars, workshops as well as publications in relevant
peer reviewed journals. The findings of this project will
be freely available to other researchers and graduate
students on request in the form of a final report.
Abbreviations
EFA: Exploratory factor analysis; MAs: Meta-analyses; PT: Physical therapy;
RCTs: Randomized controlled trial(s); RoB: Risk of bias; SRs: Systematic
reviews; TENS: Transcutaneous electrical nerve stimulation; TEs: Treatment
effects; WCPT: World confederation for physical therapy.
Armijo-Olivo et al. Systematic Reviews 2013, 2:88 Page 7 of 8
http://www.systematicreviewsjournal.com/content/2/1/88Competing interest
The authors declare that they have no competing interests.Authors’ contributions
Dr. Armijo-Olivo provided concept/idea/research design and writing.
Dr. Greta Cummings, Dr. Jorge Fuentes, Dr. Todd Rogers, Dr. Lisa Hartling
and Dr. Humam Saltaji provided feedback for concept/idea/research design.
All authors critically revised the study protocol and provided final approval of
the version to be published.Authors’ information
Susan Armijo-Olivo has a BSc in Physical Therapy (PT) from the Pontifical
University Catholic of Chile, a MSc PT and a PhD in Rehabilitation Sciences
from the University of Alberta. Her major field of research is diagnosis,
evaluation, and treatment of patients with musculoskeletal pain especially
temporomandibular and cervical spine disorders along with physical therapy
evidence based practice, knowledge synthesis and knowledge translation in
health research areas. Susan is interested in optimizing and validating
methods used to synthesize research and to conduct high quality research
particularly in the area of allied health professions. Her post-doctoral project
focuses on the methodological predictors of effect size estimates in PT trials.
This research is critical to accurately provide conclusions for health care and
decision making. This will help disseminate evidence in a useful and
understandable way for end-users such as patients, health care clinicians,
and policy/decision-makers. This project will be an important contribution to
the area of knowledge synthesis and translation in the physical therapy field
and allied health professions.Acknowledgements
This project is funded the Canadian Institutes of Health Research (CIHR) and
Alberta Innovates Health Solutions through a knowledge translation initiative
grant, the Knowledge Translation (KT) Canada research stipend program, and
the Physiotherapy Foundation of Canada (PFC) through a BE Schnurr
Memorial Fund Award.
The funding bodies had no input in the design, collection, analysis, and
interpretation of data; in the writing of the manuscript; and in the decision
to submit the manuscript for publication.
This Research protocol has been approved by the Ethics Board of the
University of Alberta (Pro00038172).
Dr. Susan Armijo-Olivo is supported by the Canadian Institutes of Health
Research (CIHR) through a full-time Banting fellowship, the Alberta Innovates
Health solution through an incentive award, the STIHR Training Program
from Knowledge Translation (KT) Canada, and the University of Alberta.
Dr. Greta Cummings is funded both provincially and nationally and holds a
Population Health Investigator award from the Alberta Heritage Foundation
for Medical Research (2006 to 2013). In July 2013, she holds a Centennial
Professorship at the University of Alberta (2013 to 2020).
Dr. Fuentes is supported by the Government of Chile, University of Alberta
through a Dissertation fellowship, and the University Catholic of Maule.
Dr. Lisa Hartling is supported by a Canadian Institutes of Health Research
New Investigator Salary Award.
Dr. Humam Saltaji is supported through a Clinician Fellowship Award by
Alberta Innovates - Health Solutions (AIHS), the Honorary Izaak Walton Killam
Memorial Scholarship by the University of Alberta, and the Honorary WCHRI
Award by the Women and Children’s Health Research Institute (WCHRI).
Author details
15-115A Edmonton Clinic Health Academy (ECHA), Outcomes Research
Program University of Alberta, 11405 - 87 Avenue, Edmonton, AB T6G 1C9,
Canada. 2Department of Physical Therapy, Faculty of Rehabilitation Medicine,
University of Alberta, 3-48 Corbett Hall, Edmonton T6G 2G4, Canada.
3Department of Physical Therapy, Catholic University of Maule, Talca, Chile.
4Center for Research in Applied Measurement and Evaluation (CRAME), 5-129
Education N University of Alberta, Edmonton, AB T6G 2G5, Canada.
5Department of Pediatrics, Alberta Research Center for Health Evidence
Faculty of Medicine, Dentistry University of Alberta, Edmonton, AB, Canada.
6School of Dentistry, University of Alberta, Edmonton, AB, Canada. 7Faculty of
Nursing, University of Alberta Edmonton Clinic Health Academy, 11405-87
Ave, Edmonton, AB T6G 1C9, Canada.Received: 18 July 2013 Accepted: 17 September 2013
Published: 26 September 2013References
1. Higgins JPT, Altman DG, Goetzsche PC, Juni P, Moher D, Oxman AD, Savovic
J, Schulz KF, Weeks L, Sterne JAC: The Cochrane collaboration’s tool for
assessing risk of bias in randomized trials. BMJ 2011, 343:7829. Online.
2. Khan K, Ter-Riet G, Popay J, Nixon J, Kleijnen J: Satge ii. Conducting the
review. Phase 5 study quality assessment. In Undertaking systematic
reviews of research effectiveness CRD’s guidance for those carrying out or
commissioning reviews. York: Center for Reviews and Dissemination;
2001:1–20.
3. Pildal J, Hrobjartsson A, Jorgensen KJ, Hilden J, Altman DG, Gotzsche PC:
Impact of allocation concealment on conclusions drawn from meta-
analyses of randomized trials. Int J Epidemiol 2007, 36(4):847–857.
4. Wood L, Egger M, Gluud LL, Schulz KF, Juni P, Altman DG, Gluud C, Martin
RM, Wood AJG, Sterne JAC: Empirical evidence of bias in treatment effect
estimates in controlled trials with different interventions and outcomes:
meta-epidemiological study. BMJ 2008, 336(7644):601–605.
5. Hartling L, Ospina M, Liang Y, Dryden DM, Hooton N, Seida JK, Klassen TP:
Risk of bias versus quality assessment of randomized controlled trials:
cross sectional study. BMJ 2009, 339(7728):1017.
6. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, Tugwell P,
Klassen TP: Does quality of reports of randomized trials affect estimates
of intervention efficacy reported in meta-analyses?(see comment).
Lancet 1998, 352(9128):609–613.
7. Schulz KF, Chalmers I, Hayes RJ, Altman DG: Empirical evidence of bias:
dimensions of methodological quality associated with estimates of
treatment effects in controlled trials. J Am Med Assoc 1995,
273(5):408–412.
8. Berger VW, Weinstein S: Ensuring the comparability of comparison
groups: is randomization enough? Control Clin Trials 2004,
25(5):515–524.
9. Trowman R, Dumville JC, Torgerson DJ, Cranny G: The impact of trial
baseline imbalances should be considered in systematic reviews: a
methodological case study. J Clin Epidemiol 2007, 60(12):1229–1233.
10. Hewitt CE, Kumaravel B, Dumville JC, Torgerson DJ: Assessing the impact
of attrition in randomized controlled trials. J Clin Epidemiol 2010,
63(11):1264–1270.
11. Nuesch E, Trelle S, Reichenbach S, Rutjes AWS, Burgi E, Scherer M,
Altman DG, Juni P: The effects of excluding patients from the analysis in
randomized controlled trials: meta-epidemiological study. BMJ 2009,
339(7722):679–683.
12. Bekelman JE, Li Y, Gross CP: Scope and impact of financial conflicts of
interest in biomedical research: a systematic review. J Am Med Assoc
2003, 289(4):454–465.
13. Lexchin J, Bero LA, Djulbegovic B, Clark O: Pharmaceutical industry
sponsorship and research outcome and quality: systematic review.
Br Med J 2003, 326(7400):1167–1170.
14. Kjaergard LL, Als-Nielsen B: Association between competing interests and
authors’ conclusions: epidemiological study of randomized clinical trials
published in the BMJ. Br Med J 2002, 325(7358):249–252.
15. Armijo-Olivo S, Macedo LG, Gadotti IC, Fuentes J, Stanton T, Magee DJ:
Scales to assess the quality of randomized controlled trials: a systematic
review. Phys Ther 2008, 88(2):156–175.
16. Moher D, Jadad AR, Nichol G, Penman M, Tugwell P, Walsh S: Assessing the
quality of randomized controlled trials: an annotated bibliography of
scales and checklists. Control Clin Trials 1995, 16(1):62–73.
17. Colle F, Rannou F, Revel M, Fermanian J, Poiraudeau S: Impact of quality
scales on levels of evidence inferred from a systematic review of
exercise therapy and low back pain. Arch Phys Med Rehabil 2002,
83(12):1745–1752.
18. Herbison P, Hay-Smith J, Gillespie WJ: Adjustment of meta-analyses on the
basis of quality scores should be abandoned. J Clin Epidemiol 2006,
59(12):1249.e1–1249.e11.
19. Armijo-Olivo S, Stiles C, Hagen N, Biondo P, Cummings G: Assessment of
study quality for systematic reviews: a comparison of the Cochrane
collaboration risk of bias tool and the effective public health practice
project quality assessment tool: methodological research. J Eval Clin Pract
2010. In press.
Armijo-Olivo et al. Systematic Reviews 2013, 2:88 Page 8 of 8
http://www.systematicreviewsjournal.com/content/2/1/8820. Higgins J, Altman D: Chapter 8: assessing risk of bias in included studies.
In Cochrane handbook for systematic reviews of interventions. Version 5.0
Edition 1 (2009). Edited by Higgins J, Green S. Chichester, UK: Wiley; 2008.
21. Kunz R, Autti-Ramo I, Anttila H, Malmivaara A, Makela M: A systematic
review finds that methodological quality is better than its reputation but
can be improved in physiotherapy trials in childhood cerebral palsy.
J Clin Epidemiol 2006, 59(12):1239–1248.
22. Therapy WCP: Position statement: standards of physical therapy practice.
World Confederation for Physical Therapy; 2011:1–45. http://www.ascon.
info/100115%20PT%20regulation-E.pdf.
23. Detection of associations between trial quality and effect sizes. http://www.
ncbi.nlm.nih.gov/books/NBK84249/.
24. Nuesch E, Reichenbach S, Trelle S, Rutjes AWS, Liewald K, Sterchi R,
Altman DG, Juni P: The importance of allocation concealment and
patient blinding in osteoarthritis trials: a meta-epidemiologic study.
Arthritis Care Res 2009, 61(12):1633–1641.
25. Van-Tulder MW, Suttorp M, Morton S, Bouter LM, Shekelle P: Empirical
evidence of an association between internal validity and effect size
in randomized controlled trials of low-back pain. Spine 2009,
34(16):1685–1692.
26. Sterne JAC, Juni P, Schulz KF, Altman DG, Bartlett C, Egger M: Statistical
methods for assessing the influence of study characteristics on
treatment effects in ‘meta-epidemiological’ research. Stat Med 2002,
21(11):1513–1524.
27. Cohen J: Chapter 1: the concepts of power analysis. In Statistical power
analysis for the behavioral sciences. Second edition. Edited by Cohen J.
Hillsdale, NJ: Academic Press Inc; 1988:1–17.
28. DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials
1986, 7(3):177–188.
29. Stevens J: Chapter 11. exploratory and confirmatory factor analysis. In
Applied multivariate statistics for the social sciences. Edited by Stevens J.
Mahwah, NJ: L Erlbaum; 2002:385–470.
30. Field AP: Chapter 15: exploratory factor analysis. In Discovering statistics
using SPSS: (and sex and drugs and rock ‘n’ roll). Edited by Field AP.
Los Angeles (that is, Thousand Oaks, CA); London: SAGE Publications;
2009:619–680.
31. Linstone HA, Turoff M: The Delphi method: techniques and applications.
London: Reading, Mass: Addison-Wesley Pub. Co, Pearson PLC, Advanced
Book Program; 1975.
32. Loo R: The Delphi method: a powerful tool for strategic management.
Policing 2002, 25(4):762–769.
doi:10.1186/2046-4053-2-88
Cite this article as: Armijo-Olivo et al.: How should we evaluate the risk
of bias of physical therapy trials?: a psychometric and meta-
epidemiological approach towards developing guidelines for the
design, conduct, and reporting of RCTs in Physical Therapy (PT) area: a
study protocol. Systematic Reviews 2013 2:88.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
